• Publications
  • Influence
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain
Clinical and neurobiological findings suggest that the cannabinoids and the endocannabinoid system may be implicated in the pathophysiology and treatment of schizophrenia. We described that theExpand
  • 46
  • 6
  • PDF
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
Movement disorders such as Parkinson's disease and dyskinesia are highly debilitating conditions linked to oxidative stress and neurodegeneration. When available, the pharmacological therapies forExpand
  • 47
  • 4
  • PDF
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa, has been reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects. We have recentlyExpand
  • 58
  • 3
Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
OBJECTIVES Clinical and neurobiological findings suggest that cannabinoids and their receptors are implicated in schizophrenia. Cannabidiol (CBD), a non-psychotomimetic compound of the CannabisExpand
  • 34
  • 2
Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: The SHR strain
Studies have suggested that the endocannabinoid system is implicated in the pathophysiology of schizophrenia. We have recently reported that Spontaneously Hypertensive Rats (SHRs) present a deficitExpand
  • 40
  • 1
Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia
Currently, the pharmacotherapy of schizophrenia is still associated with significant side effects and high rates of treatment resistance, causing a great deal of suffering to patients and theirExpand
  • 21
  • 1
Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats
Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson’s disease patients, CBDExpand
  • 22
  • 1
  • PDF
Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia
Schizophrenia is considered a debilitating neurodevelopmental psychiatric disorder and its pharmacotherapy remains problematic without recent major advances. The development of interventions able toExpand
  • 16
  • PDF
Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy
Schizophrenia is a severe psychiatric disorder that involves positive, negative and cognitive symptoms. Prepulse inhibition of startle reflex (PPI) is a paradigm that assesses the sensorimotor gatingExpand
  • 16
  • PDF
Peripubertal exposure to environmental enrichment prevents schizophrenia-like behaviors in the SHR strain animal model
Schizophrenia is a highly disabling mental disorder, in which genetics and environmental factors interact culminating in the disease. The treatment of negative symptoms and cognitive deficits withExpand
  • 8